Citigroup Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $355

Benzinga Newsdesk www.benzinga.com Positive 72.6%

Neg 0% Neu 0% Pos 72.6%

Comments

No comments yet. Be the first!